Bimodal release ondansetron for acute gastroenteritis among adolescents and adults: A randomized clinical trial

Robert A. Silverman
*Feinstein Institute for Medical Research*

Stacey L. House
*Washington University School of Medicine in St. Louis*

Andrew C. Meltzer
*George Washington University*

Barry Hahn
*Northwell Health*

Luis M. Lovato
*Olive View-UCLA Medical Center*

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

**Recommended Citation**
https://digitalcommons.wustl.edu/open_access_pubs/8858

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
Robert A. Silverman, Stacey L. House, Andrew C. Meltzer, Barry Hahn, Luis M. Lovato, Jahn Avarello, Joseph B. Miller, Ira N. Kalfus, Reza Fathi, Gilead Raday, Terry F. Plasse, and Eric C. Yan

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/8858
Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults
A Randomized Clinical Trial

Robert A. Silverman, MD, MS; Stacey L. House, MD, PhD; Andrew C. Meltzer, MD; Barry Hahn, MD; Luis M. Lovato, MD; Jahn Avarello, MD; Joseph B. Miller, MD, MS; Ira N. Kalfus, MD; Reza Fathi, PhD; Gilead Raday, MSc; Terry F. Plasse, MD; Eric C. Yan, PhD

Abstract

IMPORTANCE Vomiting resulting from acute gastroenteritis is commonly treated with intravenous antiemetics in acute care settings. If oral treatment were beneficial, patients might not need intravenous administered hydration or medication. Furthermore, a long-acting treatment could provide sustained relief from nausea and vomiting.

OBJECTIVE To determine whether an experimental long-acting bimodal release ondansetron tablet decreases gastroenteritis-related vomiting and eliminates the need for intravenous therapy for 24 hours after administration.

DESIGN, SETTING, AND PARTICIPANTS This placebo-controlled, double-blind, randomized clinical trial included patients from 19 emergency departments and 2 urgent care centers in the United States from December 8, 2014, to February 17, 2017. Patients 12 years and older with at least 2 vomiting episodes from presumed gastroenteritis in the previous 4 hours and symptoms with less than 36 hours’ duration were randomized using a 3:2 active to placebo ratio. Analyses were performed on an intent-to-treat basis and conducted from June 1, 2017, to November 1, 2017.

INTERVENTION Bimodal release ondansetron tablet containing 6 mg of immediate release ondansetron and 18 mg of a 24-hour release matrix for a total of 24 mg of ondansetron.

MAIN OUTCOMES AND MEASURES Treatment success was defined as no further vomiting, no need for rescue medication, and no intravenous hydration for 24 hours after bimodal release ondansetron administration.

RESULTS Analysis included 321 patients (mean [SD] age, 29.0 [11.1] years; 195 [60.7%] women), with 192 patients in the bimodal release ondansetron group and 129 patients in the placebo group. Treatment successes were observed in 126 patients in the bimodal release ondansetron group and 70 patients in the placebo group (65.6%) compared with 70 patients in the placebo group (54.3%), with an 11.4% (95% CI, 0.3%-22.4%) absolute probability difference. The proportion of treatment success was 21% higher among patients who received bimodal release ondansetron compared with those who received a placebo (relative risk, 1.21; 95% CI, 1.00-1.46; P = .04). In an analysis including only patients with a discharge diagnosis of acute gastroenteritis and no major protocol violations, there were 123 treatment successes (69.5%) in the bimodal release ondansetron group compared with 67 treatment successes (54.9%) in the placebo group (relative risk, 1.27; 95% CI, 1.05-1.53; P = .01). Adverse effects were infrequent and similar to the known safety profile of ondansetron.

(continued)
Abstract (continued)

CONCLUSIONS AND RELEVANCE  This randomized clinical trial found that a long-acting bimodal release oral ondansetron tablet was an effective antiemetic among adolescents and adults with moderate to severe vomiting from acute gastroenteritis. The drug benefits extended to 24 hours after administration. Bimodal release ondansetron may decrease the need for intravenous access and emergency department care to manage acute gastroenteritis.

TRIAL REGISTRATION  ClinicalTrials.gov identifier: NCT02246439

Introduction

Acute gastroenteritis is a common illness, with approximately 179 million episodes occurring in the United States each year, resulting in 600,000 hospitalizations and 5,000 deaths. Viruses are the most common identifiable cause, and disease occurs throughout the year, with outbreaks most frequent in the winter and spring. The disease is spread easily and clusters occur when people gather in close quarters or when food or water become contaminated with the virus.

Nausea, vomiting, and diarrhea are typical symptoms of acute gastroenteritis, and other symptoms include fever, abdominal pain, and malaise. Dehydration is an important contributor to the morbidity associated with gastroenteritis, and fluid repletion is a mainstay of treatment. The illness is usually self-limited, and for most individuals, nausea and vomiting are the rate-limiting factors for successful fluid replacement. Patients unable to tolerate oral hydration may need intravenous fluids in the emergency department (ED) or other acute care settings.

Medications commonly used to treat nausea and vomiting in the acute care setting include ondansetron, metoclopramide, and prochlorperazine. Several pediatric studies, most involving children younger than 12 years, have demonstrated a reduction in the need for intravenous hydration and immediate hospitalization using oral or intravenous ondansetron to treat gastroenteritis-related emesis. In contrast, a Cochrane review indicated a paucity of studies evaluating adults treated in the ED and concluded there was no evidence to support the superiority of any antiemetic drug, oral or intravenous, over placebo in treating nausea and vomiting. Vomiting is a common complaint in the ED, and even without evidence-based guidance, these drugs are routinely given to adolescents and adults for a range of conditions, including acute gastroenteritis. Ondansetron is the most widely used antiemetic in the acute care setting, with over 21.7 million uses annually and is second only to sodium chloride as the most commonly prescribed drug in EDs in the United States.

The bimodal release ondansetron tablet used in this study is an investigational 24 mg tablet that contains 6 mg of immediate release ondansetron and 18 mg of ondansetron in an extended release matrix. The drug was developed to provide therapeutic blood levels of ondansetron soon after administration and sustain therapeutic activity for up to 24 hours. Oral administration could potentially avoid the costs, discomfort, and resources associated with intravenous therapy and lead to fewer ED visits for acute gastroenteritis. Furthermore, this formulation could potentially avoid repeated dosing and reduce recurrent symptoms that occur with shorter acting agents.

In this multicenter randomized clinical trial (RCT), we tested the safety and efficacy of bimodal release ondansetron among adolescents and adults who presented to EDs or urgent care centers with nausea and vomiting due to acute gastroenteritis. The main goal of this study was to determine whether a bimodal release ondansetron tablet quickly relieves symptoms and prevents further vomiting for 24 hours without the need for rescue medication or intravenous fluid management.
Methods

Trial Design
This was a double-blind, placebo-controlled, parallel-group RCT evaluating the safety and efficacy of bimodal release ondansetron. The trial protocol and statistical analysis plan are presented in Supplement 1. The study was approved by the investigational review board for each participating institution. Written informed consent was obtained from participants 18 years and older, and study participants aged 12 to 17 years required both consent from a parent or guardian and assent from the participant. This study is reported following the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.

Setting and Participants
Individuals 12 years and older who presented to 1 of 19 EDs or 2 urgent care centers in the United States with symptoms of acute gastroenteritis were screened for eligibility from December 8, 2014, to February 17, 2017. Those with 2 or more episodes of vomiting in the 4 hours prior to arrival and with duration of vomiting less than 36 hours were eligible for enrollment. Among the exclusion criteria were pregnancy, having recently undergone an abdominal surgical procedure, any history of bariatric surgical procedures or bowel obstruction, unhealthy alcohol use or illicit drug use, an electrocardiographic corrected QT interval greater than 450 ms on ED arrival, concomitant use of any drug known to prolong the QT interval, evidence of severe dehydration, or having serious medical comorbidities, including heart failure or severe renal or liver disease, or a presumed diagnosis other than acute gastroenteritis. Individuals with type 2 diabetes could be enrolled if they were not using insulin and their bedside glucose level at the time of enrollment was less than 200 mg/dL (to convert to millimoles per liter, multiply by 0.0555). Complete inclusion and exclusion criteria are presented in the eAppendix in Supplement 2.

Patients described current nausea using a 5-point Likert numeric rating scale that included written cues, with 0 indicating none (ie, no nausea) and 4 indicating the most severe symptoms (ie, nausea as bad as it can be). Initially, only patients 50 years and older were required to have data on baseline complete blood count, biochemical profile, and urinalysis results. A protocol amendment early in the study required all patients 40 years and older and those of any age with diabetes to have data from these baseline assessments. After approximately half of the required patients were enrolled, the protocol was modified at the request of the US Food and Drug Administration to include a baseline complete blood count and biochemical blood testing, including potassium and magnesium levels, and an electrocardiogram at baseline and 4 hours after dosing for all subjects.

Randomization and Study Procedures
A computer-generated allocation sequence was used for randomization, and a central call-in center directed stratification by age (<18 vs ≥18 years). The study drug was administered in a 3:2 active to placebo ratio. The experimental drug or a like-appearing placebo tablet was sealed in a box identified only by an assigned study number. After obtaining consent, the on-site clinical investigator contacted the central randomization call-in center and was directed to use the numbered sealed box corresponding to the randomized allocation. No information regarding the contents of the numbered sealed box was provided to the study investigator.

The allocated study tablet was administered before any ED intervention. If the tablet was vomited within 15 minutes of administration, another tablet was given. If vomiting first occurred between 15 and 30 minutes after administration of the first tablet, another tablet was not given and the patient was permitted to continue the study.

Oral ingestion of fluids was encouraged during the ED stay to treat dehydration according to clinical status and the patient’s ability to tolerate oral hydration. Additional testing, including imaging or laboratory tests, could be performed any time at the discretion of the treating clinician. Intravenous preparations of other medications, such as antibiotics, were permitted as long as the
infusion volume was less than 100 mL. At 4 hours after study drug ingestion, the patient was assessed for discharge, although the duration of ED treatment could exceed 4 hours if needed. Patients who were ED treatment successes were discharged with 3 additional study tablets to take 1 every 24 hours as needed for up to 3 days.

Antipyretic, antidiarrheal, proton pump inhibitor, and antacid medications were permitted at any point during the study. For patients whose treatment failed, metoclopramide was the suggested default rescue medication. Ondansetron and any other 5-HT3 antagonist were not permitted for at least 24 hours after study drug administration.

At discharge, patients were given diary cards to record any episodes of vomiting, bowel movements, and severity of nausea, as well as other symptoms of gastroenteritis, adverse events, and any medications taken, whether for gastroenteritis or other indications. Patients were contacted daily by telephone to retrieve the relevant information.

**Primary End Point Definition**

The primary end point was treatment success, defined as meeting all 3 of the following criteria from 30 minutes through 24 hours after the first dose of study medication: (1) without further vomiting, (2) without rescue medication for nausea or vomiting, and (3) no intravenous hydration.

**Outcomes**

The primary outcome was the frequency of treatment success at 24 hours after study tablet administration. The study population included all patients who received a tablet, even if the tablet was vomited soon after administration. Patients randomized but not treated because they were found ineligible before receiving the tablet (eg, because of positive results on a pregnancy test) were excluded from the study analysis. Therefore, the primary efficacy analysis was a modified intention to treat rather than a strict intention-to-treat analysis. Per-protocol secondary analyses determined treatment success among patients with a final discharge of acute gastroenteritis and no major inclusion violations. An additional efficacy outcome was the frequency of treatment success at 4 days. The safety population was defined as any patient given the study medication, including those who were unable to swallow or vomited soon after medication administration.

**Statistical Analysis**

It was estimated that treatment would fail for 40% of the placebo group during the 24 hours after initial dosing and that bimodal release ondansetron would reduce the frequency of treatment failure by approximately 50%, ie, to a rate of 20% in the active treatment group. To demonstrate a statistically significant decrease in the incidence of vomiting with a 2-tailed \( P \) value of .01 and power of 90%, 320 patients were needed, with plans for 192 patients randomized to the active drug and 128 patients randomized to placebo.

The primary result was expressed as the relative risk (RR) adjusted for age using the Mantel-Haenszel method. The \( P \) value was calculated using the Cochran-Mantel-Haenszel test. Patients who dropped out of the study before 24 hours were imputed as treatment failures. The responder analysis through 4 days reported statistics that mirrored the primary end point analysis. Data analyses were conducted using SAS statistical software version 9.4 (SAS Institute). For all analyses, a 2-tailed \( P \) value of less than .05 was considered statistically significant. Data were analyzed from June 1, 2017, to November 1, 2017.

**Results**

**Demographic and Clinical Characteristics**

A total of 330 patients were randomized, and 321 were included in the final analysis (mean [SD] age, 29.0 [11.1] years; 195 [60.7%] women), with 192 patients randomized to the bimodal release ondansetron group and 129 patients randomized to the placebo group (Figure). Twenty-six patients
(8%) were younger than 18 years. The bimodal release ondansetron and placebo groups appeared similar for age and sex at baseline (Table 1). Most patients had severe nausea at the time of drug administration, although the bimodal release ondansetron group had worse nausea at the time of randomization than the placebo group with 58 patients (30.2%) in the bimodal release ondansetron group and 27 patients (20.9%) in the placebo group reporting nausea was as bad as it could be. Other clinical variables were similar among the 2 treatment groups. All but 7 patients (5 in the bimodal release ondansetron group, 2 in the placebo group) had a final diagnosis of acute gastroenteritis.

**Primary Outcome**
In the modified intention-to-treat analysis, a total of 126 treatment successes (65.6%) were observed in the bimodal release ondansetron group compared with 70 treatment successes (54.3%) in the placebo group. The absolute probability difference for treatment success between the 2 groups was 11.4% (95% CI, 0.3%-22.4%). The proportion of treatment success was 21% higher among patients who received bimodal release ondansetron compared with those who received the placebo (RR, 1.21; 95% CI, 1.00-1.46; P = .04) (Table 2).

**Secondary Outcomes**
In the per-protocol analysis, a total of 123 treatment successes (69.5%) were observed in the bimodal release ondansetron group compared with 67 treatment successes (54.9%) in the placebo group, and the absolute probability difference for treatment success was 14.6% (95% CI, 3.0%-25.8%). The proportion of treatment success was 27% higher for patients who received bimodal release ondansetron compared with those who received the placebo (RR, 1.27; 95% CI, 1.05-1.53; P = .01) (Table 2).

Fifteen patients required repeated dosing because of vomiting in the first 15 minutes after tablet ingestion, including 8 patients (4.2%) in the bimodal release ondansetron group and 7 patients (5.4%) in the placebo group. Among these, 3 patients in the bimodal release ondansetron group were treatment successes and 1 patient in the placebo group was a treatment success.

Patients for whom treatment did not fail were given 3 additional tablets on discharge and directed to take 1 as needed every 24 hours. Most patients did not take additional doses after leaving the ED or urgent care center, with 20 of 196 discharged patients (10.2%) taking all 3 additional doses over the subsequent 3 days. Four days after initial ED discharge, treatment was successful for 114 patients (59.4%) in the bimodal release ondansetron group and 67 patients (51.9%) in the placebo group (RR, 1.14; 95% CI, 0.93-1.40; P = .19). A total of 4 patients (2.1%) in the bimodal release ondansetron group and 4 patients (3.1%) in the placebo treatment group returned to the ED for gastrointestinal symptoms within 4 days of initial dosing.

---

**Figure. CONSORT Flow Diagram**

- **198** Allocated to bimodal release ondansetron
  - **6** Did not receive allocated intervention
    - 1 Received defective kit
    - 1 Received antiemetic before the intervention
    - 4 Disqualified for another reason

- **128** Allocated to placebo
  - **4** Did not receive allocated intervention
    - 1 Received study pill that was not based on allocation
    - 1 Withdrew consent
    - 2 Disqualified for another reason

- **330** Patients randomized
  - **192** Patients analyzed
    - **5** Lost to follow-up at 24 h
  - **132** Patients analyzed
    - **6** Lost to follow-up at 24 h

---

* A patient was assigned to receive placebo but erroneously received an unassigned study box that turned out to contain the active drug bimodal release ondansetron. All study boxes and content were of the same appearance and the blinding remained intact. Per intent-to-treat procedure, the data were analyzed by the assigned intervention (placebo group).

* Disqualifying information obtained after consent but before administration of the study drug included pregnancy, other abnormal blood test results, or abnormal electrocardiogram results.
Fourteen patients were hospitalized during the study. Five patients (4 patients in the bimodal release ondansetron group and 1 patient in the placebo group) were hospitalized because of treatment failure. The remaining patients were hospitalized for reasons other than gastroenteritis. These hospitalizations were due to conditions not diagnosed until after the patient received study medication, including cholecystitis, bile duct stones, and small-bowel obstruction.

One or more episodes of diarrhea within 24 hours after the first dose of the study drug occurred in 35 patients (16.7%) in the bimodal release ondansetron group and 28 patients (21.7%) in the placebo group. Among patients with one or more episodes of diarrhea at 24 hours, the mean (SD) number was 2.2 (1.9) episodes in the bimodal release ondansetron group and 1.6 (1.1) episodes for the placebo group. Adverse events are presented in Table 3. Patients in the bimodal release ondansetron group, compared with the placebo group, more commonly reported constipation (9 patients [4.7%] vs 1 patients [0.8%]) and headache (22 patients [11.4%] vs 7 patients [5.5%]), as expected from the known adverse effect profile of bimodal release ondansetron.

### Table 1. Patient Demographic Characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients, No. (%)</th>
<th>Bimodal Release Ondansetron Group (n = 192)</th>
<th>Placebo Group (n = 129)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td></td>
<td>Mean (SD) 29.5 (11.9)</td>
<td>28.4 (9.7)</td>
</tr>
<tr>
<td>&lt;18</td>
<td></td>
<td>15 (7.8)</td>
<td>11 (8.5)</td>
</tr>
<tr>
<td>≥18</td>
<td></td>
<td>177 (92.2)</td>
<td>118 (91.5)</td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td>122 (63.5)</td>
<td>73 (56.6)</td>
</tr>
<tr>
<td>Weight, mean (SD), kg</td>
<td></td>
<td>79.7 (21.9)</td>
<td>76.0 (20.6)</td>
</tr>
<tr>
<td>Baseline nausea levela</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None or mild</td>
<td></td>
<td>26 (13.5)</td>
<td>18 (14.0)</td>
</tr>
<tr>
<td>Moderate</td>
<td></td>
<td>38 (19.8)</td>
<td>40 (31.0)</td>
</tr>
<tr>
<td>Severe</td>
<td></td>
<td>70 (36.5)</td>
<td>44 (34.1)</td>
</tr>
<tr>
<td>Bad as it can be</td>
<td></td>
<td>58 (30.2)</td>
<td>27 (20.9)</td>
</tr>
<tr>
<td>Final clinical diagnosis gastroenteritis</td>
<td></td>
<td>187 (97.4)</td>
<td>127 (98.4)</td>
</tr>
<tr>
<td>History of type 2 diabetes</td>
<td></td>
<td>4 (2.1)</td>
<td>5 (3.9)</td>
</tr>
<tr>
<td>Abnormal serum level, No./Total No. (%)b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potassium</td>
<td></td>
<td>12/101 (11.9)</td>
<td>2/61 (3.3)</td>
</tr>
<tr>
<td>Sodium</td>
<td></td>
<td>5/102 (4.9)</td>
<td>2/61 (3.3)</td>
</tr>
<tr>
<td>Magnesium</td>
<td></td>
<td>7/78 (9.0)</td>
<td>5/52 (9.6)</td>
</tr>
<tr>
<td>Creatinine</td>
<td></td>
<td>19/101 (18.8)</td>
<td>7/61 (11.5)</td>
</tr>
</tbody>
</table>

a Assessed using a 5-point Likert numeric rating scale with 0 indicating none (ie, no nausea) and 4 indicating nausea as bad as it can be.

b The abnormal designation is based on the laboratory parameters from each site and may represent an abnormally low or high value.

### Table 2. Treatment Success at 24 Hours

<table>
<thead>
<tr>
<th>Analysis</th>
<th>Treatment Successes, No./Total No. (%)a</th>
<th>Relative Risk (95% CI)</th>
<th>P Value</th>
<th>Absolute Difference in Success Probability, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modified intent to treat</td>
<td>Bimodal Release Ondansetron Placebo</td>
<td>Relative Risk (95% CI)</td>
<td>P Value</td>
<td>Absolute Difference in Success Probability, % (95% CI)</td>
</tr>
<tr>
<td>(n = 321)b</td>
<td>126/192 (65.6)</td>
<td>70/129 (54.3)</td>
<td>1.21</td>
<td>.04</td>
</tr>
<tr>
<td>Per-protocol (n = 299)c</td>
<td>123/177 (69.5)</td>
<td>67/122 (54.9)</td>
<td>1.27</td>
<td>.01</td>
</tr>
</tbody>
</table>

a Treatment success was defined as no further vomiting and no need for rescue medication or intravenous hydration from 30 minutes through 24 hours after the first dose of study medication.

b Primary study analysis.

c Determined treatment success among patients with a final discharge of acute gastroenteritis and no major inclusion violations.
Discussion

This RCT found showed that a single long-acting bimodal release ondansetron tablet prevented further vomiting for 24 hours after tablet ingestion among adolescents and adults presenting with symptoms of acute gastroenteritis. At study entry, all participants had vomited 2 or more times in the 4 hours prior to enrollment and most had moderate to very severe nausea on ED or urgent care arrival. Even with these acute symptoms, almost all patients tolerated the oral preparation, with fewer than 5% vomiting the medication within 15 minutes of ingestion. This demonstrates that oral antiemetic treatment is feasible for a substantial portion of symptomatic patients with acute gastroenteritis.

Ondansetron administration to treat vomiting is common practice in the acute care setting, although there are no published studies supporting this off-label use for gastroenteritis among adolescents and adults, to our knowledge. Of the few published clinical trials evaluating the efficacy of any antiemetic for undifferentiated vomiting compared with a placebo among an adult ED population, a study by Braudo et al17 found intravenous droperidol to decrease nausea at 30 minutes, while studies by Egerton-Warburton et al18 and Barrett et al19 found that ondansetron, metoclopramide and prochlorperazine were not effective. Findings in these trials were limited in that nausea, the primary study outcome, was not assessed beyond 30 minutes. A Cochrane review in 201515 concluded that among adults there is no definite evidence to support the superiority of any antiemetic drug over placebo in the acute care setting.

To our knowledge, this is the first study to demonstrate that ondansetron is beneficial to treat vomiting in the adult and adolescent acute care population and the first to specifically evaluate acute gastroenteritis. Treatment with an oral agent has the advantage of avoiding intravenous drug administration and fluid replacement. A bimodal release antiemetic tablet has the dual benefit of rapid onset of efficacy and prolonged duration of activity compared with currently available oral preparations. The sustained therapeutic action of bimodal release ondansetron contrasts with shorter acting preparations whose effect may wear off before another dose is taken, risking early recurrence of nausea or vomiting.

Compared with shorter acting preparations, time-release formulations have the advantages of dosing convenience, less fluctuation in blood levels, and better health outcomes across a number of disease states.20,21 Although not studied in gastroenteritis to our knowledge, simplification of dosing regimens and reduction in tablet burden with a once daily administration has been shown to improve adherence compared with conventional formulations with short half-lives that must be given 3 or more times per day.22,23 Among the potential disadvantages of a longer acting preparation is the reduced potential for dosage adjustment.21 In our study, metoclopramide was given to those who

| Table 3. Treatment Emergent Adverse Events With Frequency of at Least 1% |
|-----------------|-----------------|
| System Involved | Bimodal Release Ondansetron Group (n = 193) | Placebo Group (n = 128) |
| ≥1 Treatment emergent adverse events | 66 (34.2) | 36 (28.1) |
| Abdominal | | |
| Distension | 3 (1.6) | 1 (0.8) |
| Pain | 3 (1.6) | 1 (0.8) |
| Constipation | 9 (4.7) | 1 (0.8) |
| Pyrexia | 3 (1.6) | 5 (3.9) |
| Chest pain | 2 (1.0) | 2 (1.6) |
| Dizziness | 2 (1.0) | 2 (1.6) |
| Headache | 22 (11.4) | 7 (5.5) |
failed study treatment, and additional study would be needed to determine optimal rescue strategies for those who do not respond to bimodal release ondansetron.

Similar to other studies evaluating antiemetics in adults who are acutely ill, we found a relatively high rate of successful outcomes in patients who received the placebo. Among the possible explanations are that some patients were enrolled toward the end of the active symptom period for a disease with a relatively short duration, contributing to a higher natural progression of improvement. Another explanation is an enhanced response among patients taking the inactive tablet leading to a larger than expected success rate. While an RCT is the standard for determining the efficacy of an intervention, the placebo effect and other influences in an RCT are difficult to estimate, and the assumption that a drug effect is simply the difference between the drug and placebo responses has been challenged. This can result in underestimated clinical trial drug effects, particularly in studies with large placebo responses.

Another possible explanation for the placebo group response is that the protocol encouraged an oral hydration regimen soon after receiving the tablet. Past ED clinical trials suggest that intravenous hydration reduces nausea and potentially masks antiemetic effects of the study drugs. The prevention or treatment of dehydration has reduced nausea and vomiting in other conditions, such as postoperative nausea and vomiting syndrome. Our study was not designed to determine whether oral rehydration independently improves outcomes, which may have contributed to the higher than expected success rates in the placebo group, and this requires further research.

In practice, giving oral rather than intravenous therapy in the acute care setting could result in more rapid treatment and disposition using lower acuity treatment areas in which fewer personnel and resources would be needed. Treatment with bimodal release ondansetron presents other outpatient treatment options, including urgent care centers or office and clinic settings, with ED visits reserved for those who fail treatment. It may be feasible for treatment to be prescribed outside of a traditional clinical setting, such as by telephone consultation or in a telemedicine setting. Further study would be needed to confirm the safety and efficacy of providing antiemesis care in alternative treatment strategies.

Limitations
This study had limitations, including the relatively few adolescent patients enrolled; therefore, the comparison of treatment response among age subgroups was not feasible. Furthermore, most of the pediatric patients were enrolled at 1 site, which limits generalizability of the age-related results. Another limitation was the lack of confirmatory testing of the diagnosis of acute gastroenteritis. Stool sample diagnostics may not detect any pathogens, and results would not have been immediately available in the ED setting at the time of enrollment. Additionally, almost all patients had what clinicians determined to be acute gastroenteritis. Our inclusion criteria mimicked actual practice; therefore, results should be generalizable to patients treated in the acute care setting with similar symptoms.

Conclusions
In conclusion, this RCT found that a long-acting bimodal release oral ondansetron tablet was effective in treating nausea and vomiting from acute gastroenteritis. The drug appeared to work quickly, and benefits from the long acting component extended to 24 hours after tablet administration. If further studies find similar results, this drug may decrease the need for intravenous access and ED visits to manage acute gastroenteritis.
ARTICLE INFORMATION

Accepted for Publication: September 15, 2019.

Published: November 8, 2019. doi:10.1001/jamanetworkopen.2019.14988

Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2019 Silverman RA et al. JAMA Network Open.

Corresponding Author: Robert Silverman, MD, MS, Department of Emergency Medicine, Northwell Health, 270-05 76th Ave, New Hyde Park, NY 11040 (rsilverman@northwell.edu).

Author Affiliations: Feinstein Institute for Medical Research, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York (Silverman); Department of Emergency Medicine, Northwell Health, New York, New York (Silverman, Hahn, Avarello); Department of Emergency Medicine, Washington University School of Medicine, St Louis, Missouri (House); School of Medicine and Health Sciences, Department of Emergency Medicine, George Washington University, Washington, DC (Meltzer); Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York (Hahn, Avarello); Department of Emergency Medicine, Olive View-UCLA Medical Center, Sylmar, California (Lovato); Cohens Childrens Medical Center, Department of Pediatrics, Northwell Health, New York, New York (Aavrello); Department of Emergency Medicine, Henry Ford Hospital, Detroit, Michigan (Miller); RedHill Biopharma, Tel-Aviv, Israel (Kalfus, Fathi, Raday, Plasse); Atlantic Research Group, Charlottesville, Virginia (Yan).

Author Contributions: Drs Plasse and Yan had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Silverman, Avarello, Kalfus, Fathi, Raday, Plasse.

Acquisition, analysis, or interpretation of data: Silverman, House, Meltzer, Hahn, Lovato, Avarello, Miller, Kalfus, Raday, Fathi, Plasse, Yan.

Drafting of the manuscript: Silverman.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Plasse, Yan.

Obtained funding: All authors.

Administrative, technical, or material support: Kalfus, Fathi, Raday, Plasse.

Supervision: Silverman, Avarello, Kalfus, Plasse.

Conflict of Interest Disclosures: Mr Raday is an employee of Redhill and Drs Kalfus, Fathi, and Plasse are independent consultants contracted by Redhill Biopharma, a manufacturer of bimodal release ondansetron. Dr Silverman reported receiving grants from Northwell Health during the conduct of the study. No other disclosures were reported.

Funding/Support: Redhill Biopharma provided full financial and material support to conduct this study.

Role of the Funder/Sponsor: Redhill Biopharma was involved in the design and conduct of the study in collaboration with academic advisers. Redhill Biopharma employed Atlantic Research Group, a clinical research organization, to conduct or assist with the collection, management, and analysis of data. Interpretation of data was performed by Redhill Biopharma and academic advisers. Dr Silverman drafted the manuscript, and all authors assisted in the preparation and review of the manuscript. Redhill Biopharma did not have the right to veto any decision made by the academic authors for publication or the choice of journal submission.

Data Sharing Statement: See Supplement 3.

Additional Contributions: Benjamin S. Abella, MD, MPhil (Department of Emergency Medicine, University of Pennsylvania, Philadelphia); Audrey Jones, DO (McAllen Primary Care Clinic, McAllen, Texas); David Lee, MD (Department of Emergency Medicine, North Shore University Hospital, New York, New York); Lisa D. Mills, MD (Department of Emergency Medicine, UC Davis Medical Center, Sacramento, California); James R. Miner, MD (Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minnesota); Ashley Norse, MD (Department of Emergency Medicine, University of Florida, Jacksonville); Lorenzo Paladino MD (Department of Emergency Medicine, SUNY Downstate Medical Center, Brooklyn, New York); Jon Rittenberger, MD, MS (Department of Emergency Medicine, University of Pittsburgh Medical Center, Hermitage, Pennsylvania); David Sheridan, MD, MCR (Department of Emergency Medicine, Oregon Health and Science University, Portland); Robert L. Sherwin, MD (Department of Emergency Medicine, Detroit Medical Center Sinai Grace Hospital, Detroit, Michigan); Adam J. Singer, MD (Department of Emergency Medicine, Stony Brook University Hospital, Stony Brook, New York); Jason A. Tracy, MD (Department of Emergency Medicine, South Shore Hospital, South Weymouth, Massachusetts); R. Gentry Wilkerson, MD (Department of Emergency Medicine, University of Maryland Medical Center, Baltimore); and Graham Dondlinger, MD (NOVA Medical Group, Ashburn, Virginia), served as principal study investigators at their respective sites.
REFERENCES


SUPPLEMENT 1.
Trial Protocol

SUPPLEMENT 2.
eAppendix. Trial Inclusion Criteria

SUPPLEMENT 3.
Data Sharing Statement